Objective: Endovascular repair of ruptured abdominal aortic aneurysm (rAAA) is being increasingly performed despite lack of good evidence for its superiority. Other reported studies suffer from patient selection and publication bias with limited follow-up. This study is a single-center propensity score comparing early and midterm outcomes between open surgical repair (OSR) and endovascular repair of rAAA (REVAR). Methods: A retrospective review from January 2001 to November 2010 identified 312 patients who underwent rAAA repairs. Thirty-one patients with antecedent AAA repair and three with incomplete records were excluded, leaving 37 REVARs and 241 OSRs. Propensity score-based matching for sex, age, preoperative hemodynamic status, surgeon's annual AAA volume, and preoperative cardiopulmonary resuscitation was performed in a 1:3 ratio to compare outcomes. Thirty-seven REVARs were matched with 111 OSRs. Late survival was estimated by Kaplan-Meier methods. Results: Operative time and blood replacement were higher with OSR. Overall complication rates were similar (54% REVAR vs 66% OSR; P ‫؍‬ .23), except for higher incidences of tracheostomies (21% vs 3%; P ‫؍‬ .015), myocardial infarction (38% vs 18%; P ‫؍‬ .036), and acute tubular necrosis (47% vs 21%; P ‫؍‬ .009) with OSR. Operative mortality rates were similar (22% REVAR vs 32% OSR), with an odds ratio of 0.63 for REVAR (95% confidence interval ‫؍‬ [0.24, 1.48]; P ‫؍‬ .40). No differences in the incidences for secondary interventions for aneurysm-or graft-related complications were noted (22% REVAR vs 22% OSR; P ‫؍‬ .99). Kaplan-Meier estimates of 1-, 2-, and 3-year survival rates were also similar (50%, 50%, 42% REVAR vs 54%, 52%, 47% OSR; P ‫؍‬ .66). Conclusions: REVAR for rAAA does not seem to conclusively confer either acute or late survival advantages. Routine use of REVAR should be deferred until prospective, randomized trial data become available. ( J Vasc Surg 2012;56:614-20.)
While the majority of ruptured abdominal aortic aneurysms (rAAAs) are repaired by open surgical method (OSR), endovascular aneurysm repair of rAAA (REVAR) is being increasingly used to treat rAAA. This enthusiasm for REVAR was primarily borne from excellent results reported in case reports and single-center series that have adopted a standardized protocol for REVAR, 1-7 metaanalyses, [8] [9] [10] and population-based studies. [11] [12] [13] [14] [15] However, these reports invariably suffer from patient selection bias with uncontrolled confounding factors and limited follow-up. [16] [17] [18] In addition, the selection of patients is poorly reported in cohort studies, and some studies fail to discriminate urgent/ symptomatic from ruptured aneurysms. Also, poor results are rarely published in the literature. Undoubtedly, these factors may contribute to superior results observed with REVAR over OSR. Despite these limitations and the lack of good evidence for its superiority, REVAR has been espoused as the preferential mode of therapy, such that even the utility of a prospective randomized trial is debated. 16, 19 The aim of this study is to evaluate whether REVAR confers early and midterm survival benefits compared with OSR using propensity score matching for confounding variables.
METHODS

Patient population.
A retrospective review of all patients with ruptured infrarenal abdominal aortic aneurysm (rAAA) treated with REVAR or OSR between January 2001 and November 2011 at the University of Pittsburgh Medical Center (UPMC) was performed using a prospectively maintained database. Ruptured abdominal aortic aneurysm was defined as either presence of free peritoneal blood or retroperitoneal hematoma on laparotomy, or presence of blood outside the aortic wall on computed tomography scan.
Three hundred twelve patients were treated for rAAA during the study period. Patients with antecedent abdominal aortic aneurysm (AAA) repairs (four previous open repairs and 27 previous endovascular repairs) and three patients with incomplete medical records were excluded from the study. Symptomatic patients without rupture were also excluded. The remaining 288 patients form the basis for this study; 37 patients underwent EVAR and 251 patients received OSR.
After Institutional Review Board approval, demographic data, comorbidities, physiologic data at presentation, time of presentation, time interval between presentation and treatment, operative data, and postoperative data were collected from medical records for all patients.
Case selection. The UPMC is a regional tertiary referral hospital with high volume of open and emergent aortic surgery cases. Selection of treatment in each case was made by the vascular surgeon based on aortic morphology, time of presentation, hemodynamic stability, and the surgeon's own experience.
Propensity score-based matching. To reduce the confounding effects of covariate imbalance between OSR and REVAR and selection bias, propensity score-based matching was performed. The variables used for matching included sex, gender, surgeon, hemodynamic stability, and preoperative cardiopulmonary resuscitation. Patients who underwent REVAR were matched to patients who underwent OSR in a 1:3 ratio due to relative sample sizes of REVAR and OSR patients and their distributions of propensity scores. Hence, 37 patients with REVAR were matched with 111 patients with OSR, and their outcomes were analyzed.
Outcomes. All intraoperative, in-hospital and 30-day mortality, postoperative morbidity, length of stay, and transfusion of blood products were recorded. The Social Security Death Index was used to evaluate the long-term mortality.
Statistical analysis. Kaplan-Meier analysis was used to estimate the late survival rates of both patient groups. Treatment selection bias was controlled by using propen-sity score-based matching for sex, age, preoperative hemodynamic status, and surgeon's annual AAA volume. All baseline variables were included in logistic regression model to predict the probability that patient would receive REVAR vs OSR upon presentation with rAAA. The fit of the propensity score model to the data was assessed using concordance index.
RESULTS
The demographic data, comorbidities, and preoperative characteristics in each treatment group are illustrated in Table  I . There were 26 males out of 37 patients (70.3%) treated with REVAR and 69 males (62.2%) in 111 patients who underwent OSR (P ϭ .48). The mean age was 74.9 years in REVAR group and 75.6 years in OSR group (P ϭ .76).
Patients presenting with hemodynamic instability, defined as systolic blood pressure Ͻ80 mm Hg, were more likely to undergo OSR (P ϭ .03). Forty-nine patients (44%) who underwent OSR were hemodynamically unstable on presentation, compared with only 24% of patients who underwent REVAR (nine patients). This difference results from the fact that the propensity score-based matching balances the probability of being treated with REVAR as a function of multiple covariates, not each covariate directly. In addition, due to the small sample size, it was not feasible to find exact matching between the groups. The delay from presentation until treatment was not statistically significant, but there was a trend toward delay in the REVAR group; the time of presentation did not differ, either. Intraoperative variables are detailed in Table II . The operative time was significantly longer in the OSR group with higher fluid and blood product transfusion requirements. The length of stay in the intensive care unit and hospital stay were lower following REVAR, but these were not statistically significant (P ϭ .13). The REVAR group had a 7.3-day mean and 4.5-day median length of stay, compared with a 23-day mean and 10.4-day median length of stay in the OSR group.
The operative mortality rates, defined as intra-operative, in-hospital, and 30-day mortality, were not statistically different between the two groups (21.6% REVAR vs 31.5% OSR; P ϭ .34). To account for the differences in the proportion of patients with hemodynamic instability (HI), a logistic regression analysis was performed with and without adjusting for HI. The difference in mortality between REVAR and OSR adjusting for HI was not significant (P ϭ .51 with the estimated difference in log odds of mortality being Ϫ.31). Overall complication rates were similar in both groups (54% REVAR vs 66% OSR; P ϭ .23) (Table  III) . However, pulmonary failure requiring tracheostomy, myocardial infarction, and acute tubular necrosis occurred more frequently after OSR. The incidences of abdominal compartment syndrome and bleeding requiring return to the operating room did not differ.
At a mean of 3-year follow-up, the aneurysm-, graft-, or procedure-related secondary interventions were similar in both groups: nine patients (25%) after REVAR vs 26 patients (23.4%) following OSR (P ϭ .99) (Table IV) . Kaplan-Meier analysis (Fig) revealed no differences in late survival at 1, 2, and 3 years (P ϭ .66). The probability of survival after REVAR was 50%, 50%, and 42%, respectively. The corresponding figures for OSR were 54%, 52%, and 47%, respectively. Following OSR, aneurysmrelated deaths occurred in 35 of 55 deaths in the first year; 14 deaths in year 2 and year 3 each were nonaneurysmrelated deaths. Following REVAR, there were nine out of 12 aneurysm-related deaths in the first year, three deaths not related to aneurysm in the second post-REVAR year, and four deaths not related to aneurysm during the third post-REVAR year.
DISCUSSION
The perceived benefits of REVAR and improved results from selected studies [1] [2] [3] [4] [5] have led some investigators to promote an "endovascular-first" approach in the treatment of rAAA 2,20 since the first report of successful REVAR by Yusuf et al in 1994. 21 In fact, the utilization of REVAR has steadily increased in the United States; the frequency of REVAR increased over the 6-year study period from 5.9% in 2001 to 18.9% in 2006 12 ; a similar trend was also observed in the present study. Such a trend was accompanied by a decrease in mortality rates from 43% to 29% in a review of a Medicare database. 22 The literature is replete with varying results after REVAR. 17 Some publications have shown no difference in early outcomes between REVAR and OSR, 3,23,24 while some have shown superior results with REVAR. While these improved results can be found in propensity scorematched 13 or large population-based studies, 11, 12 the most salient finding in review of the literature is that centers with an instituted protocol are likely to have superior outcomes with REVAR. 2, 4, 5, 7 In a recent review of collected world experience with REVAR, the 30-day mortality was 21.2% with REVAR compared with 36.3% with OSR; in a subgroup analysis of 13 centers with standardized protocols with preferential REVAR the rate was 19.7%. 5 Not all centers with protocols are successful, however. A recent international multicenter study with preferential REVAR failed to show early survival benefit even with heavy selection bias toward OSR for patients with cardiovascular instability. 24 A recent survey of the National Surgical Quality Improvement Program (NSQIP) database showed no statistically significant reduction in mortality rate with REVAR. 25 The same findings were noted in the current study. While the lack of differences in the current study may be due to the low mortality rate with OSR for rAAA observed in our institution 26 and type II errors due to the small sample size, the results resonate the conclusion of a large populationbased study and propensity score-matched studies that stated "institutional and surgeon experience were essential to fully benefit from the use of this procedure for the treatment of rAAA" and advocated for regionalization of care to high-volume centers. [11] [12] [13] It should also be noted that administrative databases are limited by their inability to control for factors such as hemodynamic stability, surgeon's experience and preference, suitability for REVAR, referral pattern, and delay between presentation and treatment. It is likely that the OSR mortality rates reported in the literature are adversely affected by unfavorable hemodynamic and anatomic characteristics, a phenomenon that has been well documented. That there was a significantly higher proportion of patients with hemodynamic instability in the OSR group may explain, at least in part, the higher (although statistical significance was not reached) mortality rate following OSR observed in the current study. Had the current study been matched for hemodynamic stability, the mortality rate with OSR would be lower and the gap narrower; the estimated difference in mortality rates after adjusting for hemodynamic instability became even smaller.
Multiple meta-analyses, systematic reviews, and populationbased studies have shown survival advantages with REVAR. However, all these studies are flawed with heavy patient selection and publication biases, poorly controlled confounding factors, and the lack of standardized reporting. 27 Recognizing these limitations, the conclusions of these studies state that there is insufficient evidence to recommend widespread adoption of REVAR and acknowledge the need for a large prospective, multicenter randomized trial, 9 in light of the fact that two earlier prospective randomized trials (the Nottingham and the Amsterdam Acute Aneurysm [AJAX] trials) have failed to show survival benefits with REVAR. [27] [28] [29] However, some refute the validity of such a trial. 16 There have been four prospective, randomized trials that have either been conducted or are currently underway. The Nottingham trial failed to show any reduction in mortality with REVAR and was terminated due to poor recruitment. 17 The AJAX and the Endovasculaire vs Chirurgie dans les Anévrysmes Rompus (ECAR) trials have been designed to recruit hemodynamically stable REVARsuitable patients. These trials, while avoiding the ethical dilemmas of randomizing hemodynamically unstable patients, will not be able to assess the role of an endovascularfirst strategy vs open repair on an intention-to-treat basis since randomization occurs only after EVAR eligibility is determined by a computed tomography scan. The AJAX trial also failed to demonstrate any survival benefits with REVAR and has been extended to recruit 120 patients, increased from its original 80-patient recruitment goal. 27 The Immediate Management of the Patient with Rupture: Open Versus Endovascular repair (IMPROVE) trial is a large trial, planned to recruit 600 patients, that randomizes patients at the time of clinical diagnosis of rAAA regardless of cardiovascular stability and before REVAR eligibility is determined. As such, it will address the question of whether or not the endovascular-first strategy provides survival benefits over OSR. 30 It is powered to show a difference of a 14% 30-day mortality rate and will identify factors that are predictive of survival benefits. 27, 30 Widespread adoption of the endovascular-first approach for the treatment of rAAA at first glance is attractive. It is minimally invasive and associated with lower complication rates, as shown in the current study. However, implementation of such a protocol involves massive systemic changes, such as stocking of endovascular stent grafts and auxiliaries and around-the-clock availability of skilled endovascular, radiologic, and nursing teams. It is not pragmatic to undertake such systemic and systematic changes in the absence of clear evidence of REVAR's superiority. As such, an institutional protocol for REVAR has not been established at our institutions; given the size of the UPMC system, this would represent a monumental task in a variety of ways.
Furthermore, REVAR is not generalizable at present. At best, about 50% of patients with rAAA may be treated with REVAR. 25 Cardiovascular stability plays a major role in selection bias and outcome. Mehta et al 31 revealed that the mortality rate following REVAR for hemodynamically unstable patients was 41%, similar to their open repair mortality rate of 40%. 32 They also noted that mortality rates after REVAR for women (33%) and octogenarians (38%) were significantly higher than those for men (17%) and those Ͻ80 years of age (15%). Furthermore, REVAR can cause an increased risk of complications such as abdominal compartment syndrome, which has been shown to be a harbinger of poor outcome with mortality in excess of 60%. 31, 33, 34 A recent study also showed an increased risk of spinal cord ischemia with occlusion (temporary or permanent) of the hypogastric artery. 35 The benefit of REVAR was not observed all across the hospitals. While a reduction in mortality was observed in teaching hospitals with REVAR, a higher risk of in-hospital death was noted in community facilities. 22, 24 Identification of patient characteristics, aneurysm morphology, and intraoperative maneuvers that may influence the outcomes of REVAR is paramount.
In regard to midterm survival rates, the early survival benefit does not seem to provide lasting effects. Survival probabilities up to 3 years were similar between the two groups in the present study. This is consistent with the findings of earlier reports. 24, 36, 37 It has been well established that a sustained risk of mortality exists even after successful open repair of ruptured abdominal and thoracoabdominal aortic aneurysm, 26, 38, 39 and patients appear to be susceptible to it after REVAR.
There is still equipoise on what the best treatment for rAAA is. The data are conflicting, and many studies showing improved outcomes with REVAR employed it preferentially for patients with favorable anatomy and hemodynamic stability. 18, 37 Preferential REVAR should be deferred until results of prospective, randomized trials are available and predictive factors for its success are identified. Some patients may be harmed by indiscriminate insistence on REVAR.
There are some limitations to this study inherent to its retrospective nature with relatively small sample size. Despite propensity score-based matching to reduce selection bias, due to the small number of patients, complete matching was not feasible. As such, there may be a selection bias on the choice of treatment rendered. The propensity scorebased matching can only remove overt bias, but unlike randomization, it cannot be expected to remove hidden biases. Additionally, the propensity score-based method is based on the hypothesis that it balances only for the covariates that were used to construct the score. Including irrelevant covariates in propensity score-based matching model may reduce efficiency.
CONCLUSIONS
Endovascular repair for rAAA does not seem to conclusively confer either acute or late survival advantages over open repair. Wide adoption and routine use of REVAR should be deferred until there is good evidence for its superiority. 
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